Mizuho Has Lowered Expectations for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective trimmed by Mizuho from $70.00 to $60.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages have also issued reports on LIVN. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Needham & Company LLC reduced their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Stifel Nicolaus decreased their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova has an average rating of “Buy” and a consensus target price of $64.20.

LivaNova Stock Up 1.7 %

LivaNova stock opened at $41.63 on Wednesday. The company has a 50-day simple moving average of $47.40 and a 200-day simple moving average of $49.49. The firm has a market capitalization of $2.26 billion, a P/E ratio of 99.12 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a one year low of $40.37 and a one year high of $64.47.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB grew its holdings in shares of LivaNova by 22.2% in the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after acquiring an additional 12,470 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of LivaNova during the fourth quarter valued at $1,954,000. KBC Group NV boosted its position in shares of LivaNova by 130.5% in the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after purchasing an additional 56,580 shares during the period. State of New Jersey Common Pension Fund D increased its stake in LivaNova by 38.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares in the last quarter. Finally, Entropy Technologies LP acquired a new stake in LivaNova during the 3rd quarter worth about $529,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.